Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium channel subfamily T member 1 (KCNT1) is a sodium-activated potassium channel protein chiefly expressed in the brain, where it regulates neuronal excitability by controlling potassium ion efflux during action potentials. The channel comprises four alpha subunits and is critical for the development and function of neuronal circuits. Gain-of-function mutations lead to increased channel activity and are implicated in a spectrum of pharmacoresistant epileptic encephalopathies, including malignant migrating partial seizures of infancy and autosomal dominant nocturnal frontal lobe epilepsy. The channel is also known as SLACK or KCa4.1, and therapeutic research targets both its abnormal function and gene expression.
Channel blockers (e.g., tetraethylammonium) inhibit potassium efflux, modulating neuronal excitability - Channel activators (e.g., phorbol 12-myristate 13-acetate) enhance potassium channel activity, potentially affecting neuronal burst firing
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium channel subfamily T member 1 (KCNT1).